In Depth 13 Jul 2023
Gold rush over: what happens to biotech now that venture capital is out of reach?
If you were to look back just a little over two years ago to the start of 2021, then putting money into a biotech company seemed like a pretty safe bet. After all, the COVID-19 pandemic had shined a positive spotlight on the biopharmaceutical industry, and initial public offerings (IPOs) were booming. But the last […]